硝基咪唑类作为抗肿瘤药物。
Nitroimidazoles as anti-tumor agents.
机构信息
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, People's Republic of China.
出版信息
Anticancer Agents Med Chem. 2011 Sep;11(7):687-91. doi: 10.2174/187152011796817664.
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
目前癌症治疗仍然是一个令人困惑的问题。自一系列小分子被 FDA 批准为抗肿瘤药物以来，抗肿瘤药物取得了重大进展。自 20 世纪 50 年代以来，硝基咪唑类化合物作为一种具有多种生物活性的放射增敏剂，用于癌症治疗。在这篇综述中，我们重点介绍了硝基咪唑类化合物作为放射增敏剂、生物还原前药和其他类型的抗肿瘤药物在癌症治疗中的发展，以及作为抗肿瘤药物的作用机制。最后，我们还讨论了硝基咪唑类化合物作为抗肿瘤药物的前景和发展趋势。
Zotero 插件